Trial intelligence / Profile preview

Hepatitis B antibody persistence and challenge response after Infanrix hexa priming in children aged 4-5 years

2006-000556-41Phase 4Completed

Sponsor
GSK
Start
Sep 2006
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by GSK. Primary endpoints: Anti-HBs antibody response one month after challenge dose and Persistence of anti-HBs antibodies at 4-5 years of age. Started Sep 2006; status: completed.

02

Drugs

Hepatitis B vaccine
03

Conditions

hepatitis B (HBV)

Beyond the preview

Go deeper on 2006-000556-41.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-000556-41.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call